Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$14.99 USD

14.99
75,706

-0.11 (-0.73%)

Updated Aug 8, 2025 03:59 PM ET

After-Market: $14.99 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion

by Zacks Equity Research

Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.

Zacks Equity Research

Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Zacks Equity Research

What Makes Amarin (AMRN) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Has Amarin Corporation (AMRN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMRN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Amarin (AMRN) Beats Earnings & Revenues Estimates in Q3

by Zacks Equity Research

Amarin beats estimates for both earnings and revenues in the third quarter of 2019. Shares up.

Zacks Equity Research

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.

Zacks Equity Research

What's in the Cards for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.

Zacks Equity Research

Amarin (AMRN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Amarin (AMRN) closed at $16.42 in the latest trading session, marking a +0.37% move from the prior day.

Zacks Equity Research

Is a Beat in Store for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Zacks Equity Research

Implied Volatility Surging for Amarin (AMRN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Zacks Equity Research

Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMRN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

by Zacks Equity Research

Key highlights of the past week include collaborations, and other regulatory and pipeline news.

Zacks Equity Research

Amarin (AMRN) Beats Earnings & Beats Revenues in Q2

by Zacks Equity Research

Amarin beats estimates for both earnings and revenues in the second quarter of 2019. Shares up.

Zacks Equity Research

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.

Zacks Equity Research

Implied Volatility Surging for Amarin (AMRN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Zacks Equity Research

Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance

by Zacks Equity Research

Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.

Zacks Equity Research

Company News for Jul 3, 2019

by Zacks Equity Research

Companies In The News Are: DAL, AMRN, HRS, ADP

Zacks Equity Research

Amarin Rises on Priority Review for Vascepa Label Expansion

by Zacks Equity Research

Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.

Zacks Equity Research

Options Traders Expect Huge Moves in Amarin (AMRN) Stock

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Zacks Equity Research

Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1

by Zacks Equity Research

Amarin (AMRN) surpasses estimates for earnings and sales in the first quarter of 2019.

Zacks Equity Research

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.

Zacks Equity Research

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amarin (AMRN) closed at $18.99, marking a +1.06% move from the previous day.

Zacks Equity Research

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Amarin (AMRN) closed at $19.75 in the latest trading session, marking a +0.71% move from the prior day.

Zacks Equity Research

Implied Volatility Surging for Amarin (AMRN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Zacks Equity Research

Amarin (AMRN) Misses Earnings & Beats Revenues in Q4

by Zacks Equity Research

Amarin misses earnings estimates while it beats sales in the fourth quarter of 2018.